Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development

被引:0
|
作者
Badralexi, Irina [1 ]
Bordei, Ana-Maria [2 ]
Halanay, Andrei [3 ]
Radulescu, Ileana Rodica [1 ]
机构
[1] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math Methods & Models, Bucharest 060042, Romania
[2] Natl Inst Aerosp Res Elie Carafoli INCAS Bucharest, Bucharest 061126, Romania
[3] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math & Informat, Bucharest 060042, Romania
关键词
chronic myeloid leukemia; asymmetric division; immune system; imatinib; delay differential equations; MATHEMATICAL-MODEL; DELAY SYSTEMS; STABILITY; HEMATOPOIESIS; BIOLOGY; CELLS;
D O I
10.3390/math12243937
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Chronic myeloid leukemia (CML) is a hematological disorder characterized by the abnormal proliferation of leukemic cells. This study aims to model the dynamics of leukemic and healthy cell populations in CML, considering the role of the immune system and the effects of treatment with Imatinib. The model also addresses the development of treatment resistance in cells, following the Goldie-Coldman hypothesis. We employ a system of delay differential equations to simulate the interactions between leukemic cells, healthy cells, and the immune system under treatment. The results provide insights into the dynamic balance between leukemic cells, healthy cells, and immune responses, and the impact of developing resistance on treatment outcomes.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells
    Garcia-Alegria, Eva
    Carmen Lafita-Navarro, M.
    Aguado, Rocio
    Garcia-Gutierrez, Lucia
    Sarnataro, Kyle
    Ruiz-Herguido, Cristina
    Martin, Francisco
    Bigas, Anna
    Canelles, Matilde
    Leon, Javier
    CANCER LETTERS, 2016, 375 (01) : 92 - 99
  • [42] Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
    Bixby, D.
    Talpaz, M.
    LEUKEMIA, 2011, 25 (01) : 7 - 22
  • [43] Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
    D Bixby
    M Talpaz
    Leukemia, 2011, 25 : 7 - 22
  • [44] Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia
    Mancini, Manuela
    Soverini, Simona
    Leo, Elisa
    Castagnetti, Fausto
    De Benedittis, Caterina
    Gugliotta, Gabriele
    Rosti, Gianantonio
    Santucci, Maria Alessandra
    Cavo, Michele
    Martinelli, Giovanni
    BLOOD, 2015, 126 (23)
  • [45] ADHESION TO STROMAL CELLS MEDIATES IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Jaganathan, Bithiah Grace
    EXPERIMENTAL HEMATOLOGY, 2017, 53 : S95 - S95
  • [46] Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib.
    Jankovic, Radmila
    Krivokuca, Ana
    Boljevic, Ivana
    Radulovic, Sinisa
    Cavic, Milena
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
    de Lavallade, Hugues
    Finetti, Pascal
    Carbuccia, Nadine
    Khorashad, Jamshid S.
    Charbonnier, Aude
    Foroni, Letizia
    Apperley, Jane F.
    Vey, Norbert
    Bertucci, Francois
    Birnbaum, Daniel
    Mozziconacci, Marie-Joelle
    LEUKEMIA RESEARCH, 2010, 34 (02) : 254 - 257
  • [48] Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy
    Proschmann, Rick
    Baldow, Christoph
    Rothe, Tino
    Suttorp, Meinolf
    Thiede, Christian
    Tauer, Josephine T.
    Mfiller, Martin C.
    Hochhaus, Andreas
    Roeder, Ingo
    Glauche, Ingmar
    HAEMATOLOGICA, 2017, 102 (02) : E39 - E42
  • [49] Chronic myeloid leukemia in the imatinib era
    Druker, BJ
    SEMINARS IN HEMATOLOGY, 2003, 40 (02) : 1 - 3
  • [50] Imatinib in Chronic Myeloid Leukemia: an Overview
    Sacha, Tomasz
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)